Aldeyra Therapeutics, Inc. (ALDX)
0.7001
-0.04
(-5.05%)
USD |
NASDAQ |
Oct 16, 16:00
0.7018
0.00 (0.00%)
After-Hours: 20:00
Aldeyra Therapeutics Cash from Operations (Quarterly) : -4.589M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -4.589M |
| March 31, 2026 | -5.110M |
| December 31, 2025 | -5.299M |
| September 30, 2025 | -7.021M |
| June 30, 2025 | -8.555M |
| March 31, 2025 | -12.47M |
| December 31, 2024 | -12.04M |
| September 30, 2024 | -7.975M |
| June 30, 2024 | -13.22M |
| March 31, 2024 | -9.973M |
| December 31, 2023 | 0.5004M |
| September 30, 2023 | -8.025M |
| June 30, 2023 | -13.36M |
| March 31, 2023 | -9.444M |
| December 31, 2022 | -11.23M |
| September 30, 2022 | -12.57M |
| June 30, 2022 | -19.96M |
| March 31, 2022 | -12.87M |
| December 31, 2021 | -11.58M |
| September 30, 2021 | -8.434M |
| June 30, 2021 | -9.072M |
| March 31, 2021 | -13.47M |
| December 31, 2020 | -8.317M |
| September 30, 2020 | -6.238M |
| June 30, 2020 | -7.579M |
| Date | Value |
|---|---|
| March 31, 2020 | -15.36M |
| December 31, 2019 | -11.23M |
| September 30, 2019 | -7.913M |
| June 30, 2019 | -12.81M |
| March 31, 2019 | -13.03M |
| December 31, 2018 | -7.925M |
| September 30, 2018 | -7.732M |
| June 30, 2018 | -6.246M |
| March 31, 2018 | -7.955M |
| December 31, 2017 | -5.184M |
| September 30, 2017 | -4.706M |
| June 30, 2017 | -5.312M |
| March 31, 2017 | -4.187M |
| December 31, 2016 | -3.910M |
| September 30, 2016 | -3.504M |
| June 30, 2016 | -3.253M |
| March 31, 2016 | -4.481M |
| December 31, 2015 | -3.019M |
| September 30, 2015 | -2.883M |
| June 30, 2015 | -1.602M |
| March 31, 2015 | -1.844M |
| December 31, 2014 | -1.607M |
| September 30, 2014 | -1.211M |
| June 30, 2014 | -0.8945M |
| March 31, 2014 | -1.064M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Prime Medicine, Inc. | -41.05M |
| Arrowhead Pharmaceuticals, Inc. | -177.47M |
| Oncolytics Biotech, Inc. | -8.066M |
| Sangamo Therapeutics, Inc. | -19.28M |
| Sarepta Therapeutics, Inc. | 197.07M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.0231M |
| Cash from Financing (Quarterly) | -15.30M |
| Free Cash Flow | -22.04M |
| Free Cash Flow Per Share (Quarterly) | -0.0765 |
| Free Cash Flow to Equity (Quarterly) | 10.76M |
| Free Cash Flow to Firm (Quarterly) | -4.612M |
| Free Cash Flow Yield | -52.27% |